Prostatadaganat prognózisának vizsgálata ismételt biopszia segítségével.

Translated title of the contribution: The role of repeated biopsies in prognosis of prostate cancer

I. Romics, Sándor Lovász, János Szabó, László Szomor, Károly Minik, Katalin Bartók, Tibor Kerényi, B. Szende

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

INTRODUCTION: The treatment of prostate cancer is still controversial. One of the most common treatment form is the use of LHRH analogs, but its way of action is still not cleared enough. AIMS: The aim of this study was to determine the predictive value of some histological and immuno-histochemical parameters based on repeated biopsies taken from prostate carcinoma patients. PATIENTS/METHOD: At the time of diagnosis by needle biopsy the TNM stage, serum PSA level, Gleason's grade, apoptotic and mitotic index, as well as Ki67, p53 and bcl2 expression were investigated in 60 prostate carcinoma patients. Anti-androgen therapy supplemented with surgical or chemical castration (with LHRH analogs) was administered. Serum PSA-test and needle biopsy were repeated 13-14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53 and bcl2 expression. RESULTS: Forty-seven patients were alive at the end of the study (average 23.46 +/- 8.6 months) and thirteen patients died (average 25.3 +/- 14.8 months). Initial TNM stage and Gleason's score proved to be of prognostic value. Decrease in mitotic index and increase in apoptotic index during therapy proved to predict favourable long-term response to androgen ablation therapy. Similarly, lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to a favourable effect of antiandrogen and especially of LHRH analog treatment. Since the ratio between Ki67 percentage and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio may be recommended as a histologically detectable predictive factor. However, bcl2 expression did not show significant correlation with the outcome of the disease. CONCLUSION: Histological evaluation of parameters such as mitotic and apoptotic index as well as Ki67 and p53 expression in repeated biopsies during treatment may contribute to predicting the value of the actual treatment and may be useful to institute alterations in therapy.

Original languageHungarian
Pages (from-to)1619-1623
Number of pages5
JournalOrvosi Hetilap
Volume143
Issue number27
Publication statusPublished - Jul 7 2002

Fingerprint

Prostatic Neoplasms
Biopsy
Mitotic Index
Gonadotropin-Releasing Hormone
Therapeutics
Needle Biopsy
Androgens
Prostate
Carcinoma
Androgen Antagonists
Neoplasm Grading
Castration
Serum
Survivors
Apoptosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Romics, I., Lovász, S., Szabó, J., Szomor, L., Minik, K., Bartók, K., ... Szende, B. (2002). Prostatadaganat prognózisának vizsgálata ismételt biopszia segítségével. Orvosi Hetilap, 143(27), 1619-1623.

Prostatadaganat prognózisának vizsgálata ismételt biopszia segítségével. / Romics, I.; Lovász, Sándor; Szabó, János; Szomor, László; Minik, Károly; Bartók, Katalin; Kerényi, Tibor; Szende, B.

In: Orvosi Hetilap, Vol. 143, No. 27, 07.07.2002, p. 1619-1623.

Research output: Contribution to journalArticle

Romics, I, Lovász, S, Szabó, J, Szomor, L, Minik, K, Bartók, K, Kerényi, T & Szende, B 2002, 'Prostatadaganat prognózisának vizsgálata ismételt biopszia segítségével.', Orvosi Hetilap, vol. 143, no. 27, pp. 1619-1623.
Romics I, Lovász S, Szabó J, Szomor L, Minik K, Bartók K et al. Prostatadaganat prognózisának vizsgálata ismételt biopszia segítségével. Orvosi Hetilap. 2002 Jul 7;143(27):1619-1623.
Romics, I. ; Lovász, Sándor ; Szabó, János ; Szomor, László ; Minik, Károly ; Bartók, Katalin ; Kerényi, Tibor ; Szende, B. / Prostatadaganat prognózisának vizsgálata ismételt biopszia segítségével. In: Orvosi Hetilap. 2002 ; Vol. 143, No. 27. pp. 1619-1623.
@article{f0a2dd5d54a94ec79cd8cb03cfcf8112,
title = "Prostatadaganat progn{\'o}zis{\'a}nak vizsg{\'a}lata ism{\'e}telt biopszia seg{\'i}ts{\'e}g{\'e}vel.",
abstract = "INTRODUCTION: The treatment of prostate cancer is still controversial. One of the most common treatment form is the use of LHRH analogs, but its way of action is still not cleared enough. AIMS: The aim of this study was to determine the predictive value of some histological and immuno-histochemical parameters based on repeated biopsies taken from prostate carcinoma patients. PATIENTS/METHOD: At the time of diagnosis by needle biopsy the TNM stage, serum PSA level, Gleason's grade, apoptotic and mitotic index, as well as Ki67, p53 and bcl2 expression were investigated in 60 prostate carcinoma patients. Anti-androgen therapy supplemented with surgical or chemical castration (with LHRH analogs) was administered. Serum PSA-test and needle biopsy were repeated 13-14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53 and bcl2 expression. RESULTS: Forty-seven patients were alive at the end of the study (average 23.46 +/- 8.6 months) and thirteen patients died (average 25.3 +/- 14.8 months). Initial TNM stage and Gleason's score proved to be of prognostic value. Decrease in mitotic index and increase in apoptotic index during therapy proved to predict favourable long-term response to androgen ablation therapy. Similarly, lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to a favourable effect of antiandrogen and especially of LHRH analog treatment. Since the ratio between Ki67 percentage and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio may be recommended as a histologically detectable predictive factor. However, bcl2 expression did not show significant correlation with the outcome of the disease. CONCLUSION: Histological evaluation of parameters such as mitotic and apoptotic index as well as Ki67 and p53 expression in repeated biopsies during treatment may contribute to predicting the value of the actual treatment and may be useful to institute alterations in therapy.",
author = "I. Romics and S{\'a}ndor Lov{\'a}sz and J{\'a}nos Szab{\'o} and L{\'a}szl{\'o} Szomor and K{\'a}roly Minik and Katalin Bart{\'o}k and Tibor Ker{\'e}nyi and B. Szende",
year = "2002",
month = "7",
day = "7",
language = "Hungarian",
volume = "143",
pages = "1619--1623",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "27",

}

TY - JOUR

T1 - Prostatadaganat prognózisának vizsgálata ismételt biopszia segítségével.

AU - Romics, I.

AU - Lovász, Sándor

AU - Szabó, János

AU - Szomor, László

AU - Minik, Károly

AU - Bartók, Katalin

AU - Kerényi, Tibor

AU - Szende, B.

PY - 2002/7/7

Y1 - 2002/7/7

N2 - INTRODUCTION: The treatment of prostate cancer is still controversial. One of the most common treatment form is the use of LHRH analogs, but its way of action is still not cleared enough. AIMS: The aim of this study was to determine the predictive value of some histological and immuno-histochemical parameters based on repeated biopsies taken from prostate carcinoma patients. PATIENTS/METHOD: At the time of diagnosis by needle biopsy the TNM stage, serum PSA level, Gleason's grade, apoptotic and mitotic index, as well as Ki67, p53 and bcl2 expression were investigated in 60 prostate carcinoma patients. Anti-androgen therapy supplemented with surgical or chemical castration (with LHRH analogs) was administered. Serum PSA-test and needle biopsy were repeated 13-14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53 and bcl2 expression. RESULTS: Forty-seven patients were alive at the end of the study (average 23.46 +/- 8.6 months) and thirteen patients died (average 25.3 +/- 14.8 months). Initial TNM stage and Gleason's score proved to be of prognostic value. Decrease in mitotic index and increase in apoptotic index during therapy proved to predict favourable long-term response to androgen ablation therapy. Similarly, lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to a favourable effect of antiandrogen and especially of LHRH analog treatment. Since the ratio between Ki67 percentage and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio may be recommended as a histologically detectable predictive factor. However, bcl2 expression did not show significant correlation with the outcome of the disease. CONCLUSION: Histological evaluation of parameters such as mitotic and apoptotic index as well as Ki67 and p53 expression in repeated biopsies during treatment may contribute to predicting the value of the actual treatment and may be useful to institute alterations in therapy.

AB - INTRODUCTION: The treatment of prostate cancer is still controversial. One of the most common treatment form is the use of LHRH analogs, but its way of action is still not cleared enough. AIMS: The aim of this study was to determine the predictive value of some histological and immuno-histochemical parameters based on repeated biopsies taken from prostate carcinoma patients. PATIENTS/METHOD: At the time of diagnosis by needle biopsy the TNM stage, serum PSA level, Gleason's grade, apoptotic and mitotic index, as well as Ki67, p53 and bcl2 expression were investigated in 60 prostate carcinoma patients. Anti-androgen therapy supplemented with surgical or chemical castration (with LHRH analogs) was administered. Serum PSA-test and needle biopsy were repeated 13-14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53 and bcl2 expression. RESULTS: Forty-seven patients were alive at the end of the study (average 23.46 +/- 8.6 months) and thirteen patients died (average 25.3 +/- 14.8 months). Initial TNM stage and Gleason's score proved to be of prognostic value. Decrease in mitotic index and increase in apoptotic index during therapy proved to predict favourable long-term response to androgen ablation therapy. Similarly, lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to a favourable effect of antiandrogen and especially of LHRH analog treatment. Since the ratio between Ki67 percentage and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio may be recommended as a histologically detectable predictive factor. However, bcl2 expression did not show significant correlation with the outcome of the disease. CONCLUSION: Histological evaluation of parameters such as mitotic and apoptotic index as well as Ki67 and p53 expression in repeated biopsies during treatment may contribute to predicting the value of the actual treatment and may be useful to institute alterations in therapy.

UR - http://www.scopus.com/inward/record.url?scp=0037036543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037036543&partnerID=8YFLogxK

M3 - Article

C2 - 12179998

AN - SCOPUS:0037036543

VL - 143

SP - 1619

EP - 1623

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 27

ER -